Celebrations may be in order for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts have sharply increased their revenue numbers, with a view that X4 Pharmaceuticals will make substantially more sales than they'd previously expected.

Following the latest upgrade, X4 Pharmaceuticals' five analysts currently expect revenues in 2026 to be US$16m, approximately in line with the last 12 months. Losses are predicted to fall substantially, shrinking 27% to US$0.67 per share. Yet before this consensus update, the analysts had been forecasting revenues of US$9.6m and losses of US$0.73 per share in 2026. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that X4 Pharmaceuticals' revenue growth is expected to slow, with the forecast 1.7% annualised growth rate until the end of 2026 being well below the historical 76% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 23% per year. Factoring in the forecast slowdown in growth, it seems obvious that X4 Pharmaceuticals is also expected to grow slower than other industry participants.

The Bottom Line

The highlight for us was that the consensus reduced its estimated losses this year, perhaps suggesting X4 Pharmaceuticals is moving incrementally towards profitability. Fortunately, they also upgraded their revenue estimates, and are forecasting revenues to grow slower than the wider market. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at X4 Pharmaceuticals.

Analysts are clearly in love with X4 Pharmaceuticals at the moment, but before diving in - you should be aware that we've identified some warning flags with the business, such as recent substantial insider selling. You can learn more, and discover the 2 other concerns we've identified, for free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.